Garcia-Guiñon, A., Charry, P., Jimenez, M., Sarra, J., Delgado, I., de la Torre, L., . . . de Larrea, C. (2025). Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.
Citación estilo ChicagoGarcia-Guiñon, A., et al. Real-world Evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in Patients With Relapsed / Refractory Multiple Myeloma. 2025.
Cita MLAGarcia-Guiñon, A., et al. Real-world Evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in Patients With Relapsed / Refractory Multiple Myeloma. 2025.
Precaución: Estas citas no son 100% exactas.